期刊文献+

地塞米松磷酸钠诱导后雌性大鼠血浆中氨苯砜含量的测定

Determination of Dapsone in the plasma of female rats induced by Dexamethasone sodium phosphate
下载PDF
导出
摘要 目的建立测定经地塞米松磷酸钠诱导后雌性大鼠血浆中细胞色素P450 3A4(CYP3A4)探针药物氨苯砜浓度的方法。方法采用高效液相色谱法,色谱柱为Ultimate-XB C18(250 mm×4.6mm i.d.,4μm),流动相为乙腈—水(25:75),流速为1.0ml/min,紫外检测波长为258nm,柱温为30℃,进样量为30μl。结果氨苯砜血药浓度在1.024~10.24mg/L范围内线性关系良好(r=0.9935),方法回收率为97.53%~99.52%,日内、日间相对标准偏差(RSD)分别为1.2%~2.3%、2.8%~4.9%。结论本方法快速、准确、灵敏度高、专属性强,适用于大鼠血浆中氨苯砜浓度的测定。 Objective To establish the method for determination of dapsone concentration which is the probe drug of cytochrome P450 3A4 (CYP3A4) in the serum. Methods Using high performance liquid chromatography( HPLC), the chromatographic column was the Ultimate-XB C18 (250mm × 4.6mm id,4μm), the mobile phase was acetonitrile-water (25:75), the flow rate was 1.0ml/min, the UV detection wavelength was 258 nm, the column temperature was 30℃, the injection volume was 30μl. Results The plasma concentration of dapsone in the range of 1. 024~10.24mg/L showed a good linear relationship (r = 0. 9935). Method recoveries were 97.53% ~ 99.52%, intro-day and inter-days RSD were 1. 2 ~ 2.3%, 2. 8 ~ 4.9%. Conclusion This method was rapid, accurate, high sensitivity, strong specificity, and suitable for determination of dapsone concentrations in serum.
出处 《临床合理用药杂志》 2012年第29期1-3,共3页 Chinese Journal of Clinical Rational Drug Use
基金 常州市科技局指导性项目 常州四药临床药学基金资助(No:CS20109010)
关键词 高效液相色谱法 氨苯砜 地塞米松磷酸钠 细胞色素P450 3A4 大鼠 High performance liquid ehromatograghy Dapsone Dexamethasone sodium phosphate CYtBA4 Rats
  • 相关文献

参考文献7

二级参考文献68

  • 1梁中书,杨侃,陈本美.液相色谱-质谱联用法测定U937细胞内胆固醇[J].中国现代医学杂志,2004,14(20):51-53. 被引量:8
  • 2刘金来.系数倍率法测定地塞米松滴眼液的含量[J].中国医院药学杂志,1996,16(9):410-411. 被引量:8
  • 3缪丽燕,黄晨蓉,曹剑波,钱美英.肾移植病人西罗莫司血药浓度/剂量比与CYP3A5基因多态性的关系[J].中国新药与临床杂志,2007,26(7):524-527. 被引量:8
  • 4Krayenbuhl JC, Vozeb S, Kondo-OestreicherM, et al. Drug-drug interactions of new active substances : mibefradil example [J]. Eur J Clin Pharmacol, 1999, 55(8): 559-565.
  • 5Breimer DD, Schellens JH. A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans[J]. Trends Pharm Sci, 1990, 11 (6): 223-225.
  • 6U. S. FDA. Guidance for Industry - Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labelling[M]. 2006.
  • 7Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P -450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians[J]. J Pharmacol Exp Ther, 1994, 270(1): 414-423.
  • 8Robson RA, Miners JO, Matthews AP, et al. Characterization of theophylline metabolism by human liver microsomes: inhibition and immunochemical studies[J]. Biochem Pharmacol, 1988, 37(9): 1651- 1659.
  • 9Sarkar MA, Hunt C, Guzelian PS, et al. Characterization of human liver cytochromes P -450 involved in theophylline metabolism[J]. Drug Metab Disps, 1992, 20(1) : 31 -37.
  • 10Grygiel JJ, Wing LM, Farkas J, et al. Effects of allopurinol on theophylline metabolism and clearance[J]. Clin Pharmacol Ther, 1979, 26 (5) : 660 -667.

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部